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Abstract
Background: Major depression is one of the most debilitating diseases in terms of quality of life. Less than half of
patients suffering from depression can achieve remission after adequate antidepressant treatment. Another promising
treatment option is cognitive-behavior therapy (CBT). However, the need for experienced therapists and substantive
dedicated time prevent CBT from being widely disseminated.
In the present study, we aim to examine the effectiveness of switching antidepressants and starting a
smartphone-based CBT program at the same time, in comparison to switching antidepressants only, among
patients still suffering from depression after adequate antidepressant treatment.
Methods/design: A multi-center randomized trial is currently being conducted since September 2014. The
smartphone-based CBT program, named the “Kokoro-App,” for major depression has been developed and its feasibility
has been confirmed in a previous open study. The program consists of an introduction, 6 sessions and an epilogue,
and is expected to be completed within 9 weeks by patients. In the present trial, 164 patients with DSM-5 major
depressive disorder and still suffering from depressive symptoms after adequate antidepressant treatment for more
than 4 weeks will be allocated to the Kokoro-App plus switching antidepressant group or the switching antidepressant
alone group. The participants allocated to the latter group will receive full components of the Kokoro-App after
9 weeks.
The primary outcome is the change in the total score on the Patient Health Questionnaire through the 9 weeks
of the program, as assessed at week 0, 1, 5 and 9 via telephone by blinded raters. The secondary outcomes
include the change in the total score of the Beck Depression Inventory-II, change in side effects as assessed by
the Frequency, Intensity and Burden of Side Effects Rating, and treatment satisfaction.
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Discussion: An effective and reachable intervention may not only lead to healthier mental status among depressed
patients, but also to reduced social burden from this illness. This paper outlines the background and methods of a trial
that evaluates the possible additive value of a smartphone-based CBT program for treatment-resistant depression.
Trial registration: UMIN-CTR: UMIN000013693 (registered on 1 June 2014)
Keywords: Behavior therapy, Cognitive therapy, Computer-assisted therapy, Depression, Randomized controlled trials
Background
Major depression is the second leading cause of deterior-
ation of quality of life in humankind [1]. The economic
loss due to depression is estimated at approximately 2
trillion yen per year in Japan [2]. Approximately 30,000
people a year die due to suicide in Japan. Half of these
suicide victims are estimated to suffer from depression
immediately before committing suicide [3].
The first-line treatment for depression in clinical settings
is pharmacotherapy, especially antidepressant treatment;
however, less than 50 % of patients receiving acute-phase
antidepressant treatment for 2 to 4 months can achieve re-
mission [4]. Other effective treatment options for depres-
sion include cognitive-behavior therapy (CBT); this has
been shown to be as efficacious as pharmacotherapy [5]
and to be more efficacious when combined with pharma-
cotherapy than pharmacotherapy alone [6]. CBT can,
therefore, be a viable treatment option not only for patients
preferring CBT to pharmacotherapy but also for patients
still suffering from depression after an adequate trial of
antidepressant treatment.
However, patients willing to receive CBT can rarely do
so even in developed countries, because a typical course
of CBT consists of sixteen 1-hour face-to-face sessions led
by an experienced therapist. On the other hand, CBT de-
livered via the Internet or computers has been recently
provided in Western countries, including Australia, the
United Kingdom, the Netherlands and Sweden. The effi-
cacy of computer-based or Internet-based CBT has been
examined in previous systematic reviews. A systematic re-
view and meta-analysis, combining results from 6 ran-
domized controlled trials (RCTs) with 645 participants,
estimated an effect size of computer-based CBT to be 0.78
(95 % confidence interval (CI): 0.59 to 0.63) in comparison
with treatment as usual (TAU) or waiting-list controls [7].
Another systematic review combining results from 16
RCTs with 2807 participants showed that computer-based
CBT led to a greater proportion of dropouts but to better
efficacy at an effect size of 0.48 (0.33 to 0.63) in the short-
term follow up than those in control conditions, whilst to
neither superiority nor inferiority in the long term [8].
In the wake of recent developments in information and
communication technology (ICT), CBT delivered via
smartphones can be a better treatment option for depres-
sion than a computer-based one in terms of accessibility
and portability. A clinical trial involving 52 participants in
the community has shown that smartphone-based CBT
was not inferior to computer-based CBT at 3-month fol-
low up [9].
Given the vast number of patients with depression and
the still very limited accessibility of effective CBT for
them, it will be very meaningful and helpful to develop a
CBT program taking advantage of this rapidly evolving
ICT. In the present study, we aim to examine the effect-
iveness of adding a smartphone-based CBT program to
switching antidepressants in comparison to that of
switching antidepressants alone, for patients still suffer-
ing from depression after adequate antidepressant treat-
ment. Among antidepressants, a systematic review and
multiple-treatment meta-analysis evaluating the com-
parative efficacy of 12 newer antidepressants has sug-
gested that escitalopram and sertraline are the most
favorable in terms of efficacy and acceptability [10]. We
aim to examine the effectiveness of switching from the
previous antidepressant to escitalopram or sertraline and
starting a smartphone-based CBT program at the same
time, in comparison to switching to escitalopram or
sertraline only, among patients still suffering from de-
pression after adequate antidepressant treatment. We
hypothesized that adding a smartphone-based CBT
program to switching antidepressants could lead to greater
improvement in depression symptoms among patients




A multi-center, parallel-arm, rater-blinded RCT has been
planned. Participants who still suffer from full or residual
major depressive disorder after adequate antidepressant
treatment will be randomly allocated to either of the two
intervention arms: 1) switching antidepressants to escitalo-
pram or sertraline plus smartphone-based CBT program
the “Kokoro-App” (“kokoro” means “mind” or “heart” in
Japanese) consisting of 8 sections, or 2) switching antide-
pressants to escitalopram or sertraline only for 8 weeks
after 1 week of introductory lead-in. The primary outcome
is the slope of the Patient Health Questionnaire-9 (PHQ-9)
through 0 to 9 weeks. The secondary outcomes include the
slope of the Beck Depression Inventory (BDI-II) through 0
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to 9 weeks; treatment satisfaction at 9 weeks; continuation
of antidepressant pharmacotherapy up to 9 weeks; and the
slope of the Frequency, Intensity and Burden of Side Effects
Rating (FIBSER) through 0 to 9 weeks.
Interventions
Smartphone-based CBT program: “Kokoro-App”
The smartphone-based CBT program the “Kokoro-App”
for iPhones and iPads (Apple Inc., Cupertino, CA, USA)
has been developed, based on an empirically supported
CBT manual [11–13], and pilot tested for feasibility and
acceptability. It consists of eight sections, including one
introductory section, two sessions on self-monitoring,
two sessions on behavioral activation, two sessions on
cognitive restructuring, and one epilogue.
The Kokoro-App can be completed within 7 weeks at
the fastest. The main program consists of dialogues be-
tween characters who explain the principles and skills of
CBT (Fig. 1). Homework needs to be completed by the
participant between sessions. The participant can proceed
to the next session 1 week after they start the previous
one and after they finish the homework. One session
needs approximately 30 minutes to complete. The central
trial office sends an Email to each participant to encourage
him/her to complete the session and the homework once
every week during the program.
The participants and their attending physicians can
check the entries made by the participants into the pro-
gram by looking at the website (Kokoro-App Web). They
can thus discuss the contents uploaded to the Kokoro-
App Web during their consultations.
Security of the data exchanged through the Internet
has been certificated by Secure Sockets Layer (SSL). An
identification number and a password are required to
enter the program or website when: 1) a participant logs
in to the program at week 0; 2) a participant logs in to
the Kokoro-App Web; and 3) the attending physician
logs in to the Kokoro-App Web.
Antidepressant pharmacotherapy
In the present study, antidepressants that the participants
had been taking before entry to the study will be switched
to escitalopram or sertraline. A systematic review and a
multiple-treatment meta-analysis have suggested that esci-
talopram and sertraline are the most favorable in terms of
the efficacy and acceptability among 12 newer antidepres-
sants [10]. The attending physician will start escitalopram
or sertraline at entry (week 0) and aim to stop antidepres-
sants other than these two by week 5 and to prescribe ei-
ther 5–10 mg/day of escitalopram or 25–100 mg/day of
sertraline at week 5.
Fig. 1 Screen shots from the Kokoro-App on an iPhone
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Concomitant interventions
From week 0 through week 9, mood stabilizers (e.g.,
lithium, valproic acid, carbamazepine and lamotri-
gine), antipsychotics, electroconvulsive therapy, re-
petitive transcranial magnetic stimulation, individual
CBT, and individual interpersonal therapy will not be
allowed. Two antidepressant drugs may be prescribed
until week 5 while the drug previously prescribed
before entry is tapered and discontinued. After week
5, either escitalopram or sertraline should be pre-
scribed as antidepressant monotherapy.
Any psychotherapy that is not specifically designed
for depression, anxiolytics and hypnotics can be pre-
scribed, and dosage of these can be changed between
week 0 and week 9. Group psychotherapy during this
period is allowed, but may not be changed or started.
The period after the assessment at week 9 is a follow-
up phase, and any treatment is allowed at the attending
physician’s discretion as TAU.
Participants
The inclusion criteria for the participants are:
1) Men or women aged between 25 and 59 years upon
entry into the study. We will limit participants to
those aged 25 or older because patients younger
than this age have been reported to be susceptible to
increased suicidality after taking antidepressants in
comparison with those taking placebo [14];
2) Primary diagnosis as major depressive disorder
without psychotic features, according to the
Diagnostic and Statistical Manual of Mental
Disorders, version 5 (DSM-5). This is confirmed by the
treating psychiatrist through the semi-structured
interview using the Primary Care Evaluation of Mental
Disorders (PRIME-MD) [15]. It is not necessary that
the patient satisfies the full criteria for a current major
depressive episode upon entry. As long as the patient
does not experience remission lasting for 2 months or
more, the patient is considered to be in the same
major depressive episode. Comorbid secondary
diagnosis of anxiety disorders is allowed;
3) Not having taken either escitalopram or sertraline
for the current episode;
4) Being antidepressant-resistant, defined as scoring 10
or more on the BDI-II at entry after taking one or
more kinds of antidepressants at an adequate dosage
for 4 or more weeks (corresponding to Stage I, II or
III according to the criteria by Thase and Rush [16]),
and it is judged by the attending physician that the
patients should be switched to escitalopram or
sertraline;
5) Taking only one kind of antidepressant at entry, and
not taking any antipsychotics or mood stabilizers.
Concomitant use of anxiolytics or hypnotics is
allowed;
6) Willing to do the Kokoro-App program, and being
judged suitable for the program by the attending
physician;
7) Being used to smartphones, which is confirmed by
the following conditions: a) the patient uses an
iPhone, iPad (Apple Inc., Cupertino, CA, USA),
Android smartphone or an equivalent in daily life; b)
has an Email address for daily use; and c) has a
mobile phone number for daily use;
8) Being an outpatient at entry, and having no plan to
be hospitalized more than 1 week for any reason
within 4 months;
9) Having no plan to transfer to a different hospital
within 4 months;
10) Being able to respond to assessments about
symptoms and side effects via telephone; and
11) Being able to understand and sign a written
informed consent.
The exclusion criteria include:
1) Having taken any of the following interventions for
the current episode: a) monoamine oxidase inhibitors
(corresponding to Stage IV according to the criteria of
Thase and Rush [16]); b) electroconvulsive therapy or
repetitive transcranial magnetic stimulation
(corresponding to Stage V [16]); c) both escitalopram
and sertraline; or d) face-to-face individual CBT or
face-to-face interpersonal psychotherapy;
2) Any of the following comorbid illnesses: a) past
history of schizophrenia, schizoaffective disorder, or
bipolar and related disorders according to DSM-5;
or b) current diagnosis of neurocognitive disorders,
feeding and eating disorders, substance-related and
addictive disorders or borderline personality
disorder;
3) Imminent risk of suicide as judged by the treating
physician;
4) Physical illnesses possibly interfering with
pharmacotherapy by escitalopram or sertraline,
including: a) a possible prolonged QT syndrome, as
judged through an interview with the attending
physician; b) prolonged heart-rate corrected QT
interval (QTc) in the electrocardiogram within
1 month (male: QTc > 450 ms, female: QTc >
470 ms [17]); c) taking medication known to prolong
the QT interval and being judged unsuitable to take
escitalopram or sertraline by the attending physician;
d) severe or extremely unstable cardiovascular
disease, such as current or past severe bradycardia,
congestive heart failure or hypokalemia; e) severe or
extremely unstable hepatic, renal, respiratory, blood,
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or endocrine function, or central nervous system
disease or head injury; f ) terminal stage of physical
illnesses; g) currently taking pimozide; or h) history
of hypersensitivity or allergy to escitalopram or
sertraline;
5) Being currently pregnant or breastfeeding;
6) Currently participating in another clinical
intervention study;
7) Family members living with the researchers of the
present study; or
8) Being unable to understand the written Japanese
language.
Trial sites
A participating trial site must fulfill the following eligibility
criteria:
1) Have a department of psychiatry or of
psychosomatic medicine;
2) The principal trial physician and all the participating
trial physicians at the site have understood the study
protocol; and
3) The site is within mobile phone range.
On the other hand, a trial site will be ineligible if it satis-
fies one or more of the following conditions:
1) The principal trial physician withdraws consent for
participating in the study;
2) No participant is registered for 6 months; or
3) The steering committee of the present trial judges
the site to be inappropriate to recruit participants.
Initial trial sites include Nagoya City University Hospital
in Aichi, Waseda Clinic in Gifu, Kochi University Hospital
and Atago Hospital in Kochi, Japan.
Assessment measures
Screening tools
Primary Care Evaluation of Mental Disorders (PRIME-
MD) Major depressive disorder, according to DSM-5,
will be diagnosed through semi-structured interview
using PRIME-MD [18] by the attending physicians at
baseline.
The Beck Depression Inventory-II (BDI-II) The BDI-II
is a 21-item self-report instrument to measure the severity
of depression. Its first version was developed in 1961 [19]
and a major revision was undertaken in 1996 to make the
scale more congruent with the modern diagnostic criteria
for major depression [20]. Good reliability and validity have
been reported for the Japanese version [21].
The time frame for evaluation is set to the past 2 weeks
including the day of assessment. The BDI-II will be used
for a screening tool at week 0 and participants with a total
score of 10 or more will be included in the present study.
Electrocardiogram The QTc will be checked using an
electrocardiogram within 1 month before week 0. The
QTc will be deemed prolonged if > 450 ms for males
and > 470 ms for females, respectively, and will be
checked again at week 1.
Primary outcome measure
Patient Health Questionnaire-9 (PHQ-9) The PHQ-9
consists of the 9 diagnostic criteria items of the
DSM-4 [15]. Each item is rated between 0 = “Not at
all” through 3 = “Nearly every day,” making the total
score range between 0 and 27. Excellent test-retest re-
liability and internal consistency reliability have been
reported [15, 22]. Good construct validity has been
demonstrated through associations with various sever-
ity indices [23]. The sensitivity to change is as good
as or better than extant scales [24].
Secondary outcome measures
Patients’ satisfaction with treatment The following 2
questions will be graded on a scale of 100 by patients: 1)
“To what extent has the treatment met your needs for
these two months? Please answer on a scale of 1 to 100,
presuming 60 as a passing mark”; and 2) “To what ex-
tent have you been satisfied with the treatment for these
2 months? Please answer on a scale of 1 to 100, presum-
ing 60 as a passing mark.”
Continuation of protocol treatment up to week 9 In
order to evaluate whether the Kokoro-App may have in-
terfered with pharmacotherapy as defined in the proto-
col, continuation rates of protocol pharmacotherapy at
week 9 will be compared between the intervention and
control groups. Discontinuation of pharmacotherapy is
defined as not taking a prescribed antidepressant for
more than 1 week due to any reason as judged by the at-
tending physician.
Frequency, Intensity, and Burden of Side Effects Rating
(FIBSER) FIBSER was originally used in STAR*D as a
global rating scale for side effects. The FIBSER consists
of 3 domains evaluating the frequency, intensity and se-
verity of side effects, each of which has a score from 0 to
6. The reliability and validity of the FIBSER have been
confirmed [25].
K6 K6 is a very short (6-item) self-report questionnaire to
screen for common mental disorders and to evaluate the
severity of general psychological distress [26]. Good valid-
ity and reliability have been confirmed [27], and its area
under the curve compared to “gold-standard” diagnoses of
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depressive and anxiety disorders was 0.94 [28]. The Japa-
nese version has been validated [28].
Procedures
Screening
Physicians (psychiatrists) in the recruiting sites will iden-
tify patients possibly eligible for the study by checking
diagnosis of major depressive disorder according to DSM-
5 by means of the PRIME-MD. They will also confirm
absence of a history of heart disease or current prolonged
QTc by electrocardiogram within 1 month before entry,
and check the other eligibility criteria (Fig. 2, Table 1).
Informed consent, installing the Kokoro-App and medication
at week 0
A clinical research coordinator at a recruiting clinic (site
CRC) will seek written informed consent from the can-
didate participant at the clinic at week 0. Participants
Fig. 2 Flowchart of the trial. Abbreviations: BDI-II, Beck Depression Inventory-II; CRC, clinical research coordinator; FIBSER, Frequency, Intensity, and
Burden of Side Effects Rating; PHQ-9, Patient Health Questionnaire-9; PRIME-MD, Primary Care Evaluation of Mental Disorders; TAU, treatment as usual
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will be informed that they can withdraw their consent at
any time without stating the reason and that their with-
drawal will not affect the medical services they receive.
The written informed consent will be obtained along
with the mobile phone number of the participant, with
which the central trial office can contact him or her to
assess the outcomes.
Immediately after consent, all participants will install
the Kokoro-App onto his or her smartphone with an as-
sistance of the site CRC. After successful installation, the
server will provide a password specific to each participant
via an Email to the participant. The participant will be able
to proceed to the introductory section of the Kokoro-App
by entering the password. In the introduction, the partici-
pant will practice entering some sentences into the smart-
phone and fill in a self-report measure of psychological
distress (K6). All participants will receive an interview
using the PHQ-9 and the FIBSER at the clinic via tele-
phone from the central trial office.
The attending physician of the participant will start
switching the previous antidepressant at week 0 to either
5–10 mg/day of escitalopram or 25–100 mg/day of ser-
traline. The patient will take escitalopram if he or she
has taken sertraline for the current episode, and vice
versa. If the patient has taken neither escitalopram nor
sertraline for the current episode, one of these two will
be selected by the attending physician. The maximum
dosage of escitalopram was set at 10 mg/day because: 1)
the efficacy of 20 mg/day of escitalopram has not been
proved to be superior to that of 10 mg/day [29, 30]; 2)
the tolerability of the former has been proved to be in-
ferior to that of the latter in terms of dropout rates due
to side effects [31]; and 3) a dose response has been re-
ported between dosage of escitalopram and prolonged
Table 1 Schedule for the assessments





BDI-II √ √ √ √ √
PHQ-9 √ √ √ √ √
FIBSER √ √ √ √ √
Blindness √ √ √
Treatment satisfaction √ √
Allocation √










BDI-II Beck Depression Inventory-II, CRC clinical research coordinator, FIBSER Frequency, Intensity, and Burden of Side Effects Rating, K6 6-item self-report questionnaire
to evaluate the severity of general psychological distress, PHQ-9 Patient Health Questionnaire-9, PRIME-MD Primary Care Evaluation of Mental Disorders
aBasic characteristics include sex, age, education, work status, marital status, age at first depressive episode, number of episodes, duration of the current
depressive episode, information about treatment for current episode, and current history of physical illnesses
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QT interval [32]. Anxiolytics and hypnotics can be used,
started, increased/decreased and discontinued during
the study.
Randomization and medication at week 1
An appointment at week 1 will be scheduled within 3
to 14 days from the entry. At week 1, the participant
will receive an electrocardiogram and an interview,
using the PHQ-9 and the FIBSER, via telephone from
the central trial office. Based on these results, the par-
ticipant will be classified into either of the following
two groups: A) primary comparison set: those who have
not responded or only partially responded to escitalo-
pram or sertraline (defined by the total score of the
PHQ-9 of 5 or more at week 1), are tolerant to escitalo-
pram or sertraline (defined by item 1 of the FIBSER of
3 or more and items 3 and 4 of 3 or less at week 1,
which means that the participant has been able to take
the antidepressant for 3 days or more and the intensity
and the interference with daily functions due to side ef-
fects of the medication is mild or less), and have no
problems in using the smartphones and the Kokoro-
App; B) secondary comparison set: those who have not
satisfied any of the above criteria.
Within each group, the participants will be randomly
allocated to either the combined smartphone-based
CBT and antidepressant switch group (intervention
group) or the antidepressant switch alone group (con-
trol group) at 1:1 ratio with a minimization method
using the electronic data-capturing web program (EDC)
at the central trial office. Random allocation will, there-
fore, be concealed. Clinics, number of antidepressants
previously prescribed for the index episode (3 or more
versus 2 or less), and a total score of the PHQ-9 (10 or
more versus 9 or less) at week 1 will be used as stratifi-
cation variables.
If the participant is allocated to the intervention
group, he or she will be provided with a password to
proceed to Session 1 of the Kokoro-App. If the partici-
pant is allocated to the control group, he or she will be
informed that the Kokoro-App can be resumed if the
participant is willing to do so after week 9.
With regard to antidepressants, if the participant is in-
tolerant of escitalopram or sertraline prescribed at week 0
(defined by scores of 4 or more on either item 3 or 4 of
FIBSER), the physician will suggest stopping the anti-
depressant and starting previous or new antidepressants
other than escitalopram and sertraline.
Trial period: from week 1 through week 9
For all the participants, an appointment with the at-
tending physician will be scheduled at least every
4 weeks. Visits must take place at weeks 5 and 9. The
previous antidepressant must be tapered off by week 5,
and either escitalopram or sertraline (or another anti-
depressant if the participant is intolerant of these two)
must be prescribed as monotherapy at week 5. Only
anxiolytics and hypnotics are allowed as psychotropic
drugs other than antidepressants.
For the participants allocated to the intervention group,
the physician can check the patient’s progress of the
Kokoro-App through the Kokoro-App Web, and discuss
it with the participant during consultations. If the partici-
pants allocated to the control group express interest in
CBT by week 9, the physician is allowed to suggest self-
help books about CBT but not to provide any specific
CBT sessions.
At weeks 5 and 9, the participant will receive an inter-
view, using the PHQ-9 and the FIBSER, via telephone at
the clinic from the central trial office. Depression severity
will also be assessed with the BDI-II. At week 9, an inter-
view using a scale on treatment satisfaction will also be
administered via telephone.
Follow-up period: from week 9 through week 17
After assessments at week 9, no restrictions will be
posed in terms of medications, frequency of ap-
pointments, or CBT. The participants allocated to the
control group can resume the Kokoro-App if they
wish to. At week 17, all the participants will receive
an assessment of the PHQ-9, the FIBSER and the
scale on treatment satisfaction via telephone from the
central trial office as well as to fill in a self-rating
scale of the BDI-II.
Stopping rules for participants
Dropouts from the trial The participants will be ex-
cluded from the intention-to-treat (ITT) cohort of the
trial, if it was not possible to randomize them at week 1
or if their primary diagnosis was changed before week 1.
Deviation from protocol treatment The following cases
will be considered deviation from the trial protocol; how-
ever, the participant will not be considered to have
dropped out of the trial at this stage and will receive the
protocol assessments:
1) When prohibited concurrent treatments or
prescription of the intervention antidepressant above
the maximum dosage defined in the protocol (10 mg/
day for escitalopram, and 100 mg/day for sertraline)
took place between week 0 and week 9;
2) When changes in treatment that are allowed to be
co-administered but not to be changed between week
0 and week 9 took place;
3) If the participant cannot take any pills of sertraline or
escitalopram due to side effects between week 1 and
week 9;
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4) If the participant develops a manic/hypomanic/
mixed episode, or is diagnosed with schizophrenia or
dementia between week 1 and week 9.
Discontinuation of protocol treatment If the partici-
pant meets any of the following conditions, the trial
physician can stop the antidepressant or the Kokoro-
App. The participant, however, will not be considered to
have dropped out of the trial at this stage and will re-
ceive the protocol assessments:
1) The participant wishes to stop the protocol
treatment;
2) The trial physician judges that it is difficult to
continue the protocol treatment because of serious
side effects;
3) The trial physician judges that the risk outweighs
the benefit in continuing the protocol treatment
even when no serious side effect is reported;
4) The participant becomes pregnant and the trial
physician judges that the risk outweighs the benefit
in continuing the protocol treatment;
5) The trial physician judges that it is inappropriate to
continue the protocol treatment for some other
reason.
Stopping assessment If the participant withdraws con-
sent for assessments, he/she will not be followed up.
Blindness and reliability of assessment from the central trial
office
The primary outcome (PHQ-9) and information about
side effects (FIBSER) at weeks 0, 5, 9, and 17 and treat-
ment satisfaction judged by participants at weeks 9 and
17 will be collected via telephone by central CRCs, who
are kept blind to groups to which the participant has
been allocated.
At week 5, 9 and 17 assessments, the blindness of the
central CRCs as to the participant’s treatment will be
assessed by having the CRCs guess the allocated treat-
ment by selecting one from the following: 1) I strongly
believe that the patient is allocated to the combination
group; 2) I guess that the patient is allocated to the com-
bination group but am not confident; 3) I cannot tell; 4)
I guess that the patient is allocated to the antidepressant
alone group but am not confident; and 5) I strongly be-
lieve that the patient is allocated to the antidepressant
alone group.
The inter-rater reliability of the central CRCs will
be examined by comparing the assessors’ ratings of
audio recordings of the PHQ-9 and FIBSER, recorded
in our previous study [11], with the original ratings.
In addition, five recordings in the present study will
be assessed again by another rater blinded to the
original rating in order to evaluate the inter-rater reli-
ability in the present study.
Reporting of adverse events and protection of
participants
Definition of adverse events
An adverse event is defined as any unwanted or unin-
tended sign (including laboratory exams), symptom or
disease seen in participants of the trial. According to the
“Ethical Guidelines for Clinical Studies: Questions and
Answers,” which is published by the Japanese Ministry of
Health, Labor and Welfare, severe adverse events are de-
fined as events leading to any one the following: a)
death; b) threatened death; c) admission or prolongation
of admission for treatment; d) enduring and severe im-
pairment and dysfunction; or e) congenital anomaly.
When a serious adverse event occurs, the trial physician
must notify the principal investigator within 48 hours,
regardless of the causal relationship with the trial inter-
vention. The principal investigator shall report to the
institutional review board in Kyoto University Graduate
School of Medicine within 72 hours, and notify all the co-
principal investigators. The principal investigator must
also notify all the collaborators at all the recruiting sites.
The collaborators will take the necessary measures ac-
cording to the information from the principal investigator.
If it concerns an unforeseen serious adverse event, the
principal investigator shall report it to the Ministry of
Health, Labor and Welfare.
Foreseeable adverse events
Escitalopram Frequent side effects include: nausea
(23.8 %), somnolence (23.5 %), headache (10.2 %), dry
mouth (9.6 %), dizziness (8.7 %), fatigue (7.1 %), diarrhea
(6.2 %), etc.
Serious side effects include: convulsion (unknown fre-
quency), the syndrome of inappropriate anti-diuretic
hormone secretion (SIADH) (unknown frequency), sero-
tonin syndrome (unknown frequency), prolonged QT
(unknown frequency), and ventricular tachycardia (un-
known frequency).
Sertraline Frequent side effects include: nausea (18.9 %),
somnolence (15.2 %), dry mouth (9.3 %), headache (7.8 %),
diarrhea (6.4 %), dizziness (5.0 %), etc.
Serious side effects include: serotonin syndrome (un-
known frequency), malignant syndrome (unknown fre-
quency), convulsion (unknown frequency), coma (unknown
frequency), liver dysfunction (unknown frequency), SIADH
(unknown frequency), Lyell syndrome and toxic epidermal
necrolysis (unknown frequency), and anaphylactoid symp-
toms (unknown frequency).
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Kokoro-App No specific adverse events are presumed in
participants who use the Kokoro-App. However, using the
Kokoro-App might lead to psychological distress in some
participants depending on their psychological state.
Compensation insurance
Because all the protocol antidepressant interventions are
administered within the approved regulations in Japan,
any health hazards shall be covered by the National
Health Insurance. However, because the trial involves
random allocation, we have contracted a private health
insurance (Tokio Marine and Nichido Fire Insurance
Co., Ltd.) to compensate for health hazards that have
arisen due to this trial.
Data monitoring
The trial will be supervised by the Data and Safety
Monitoring Board (DSMB). The board consists of three
independent experts in psychiatry and clinical trial
methodology. The members of the committee are inde-
pendent from the present study: Dr Teruhiko Higuchi
(Chair of the DSMB, Psychiatrist, National Center for
Neurology and Psychiatry), Professor Yoshio Hirayasu
(Psychiatrist, Yokohama City University) and Dr Akiko
Kada (Biostatistician, National Hospital Organization
Nagoya Medical Center). The purpose of DSMB is to
check the data monitoring reports prepared by the data
center and make recommendations to the principal in-
vestigator, where necessary.
Ethical issues
The present study is subject to the ethical guidelines
for clinical studies published by the Japanese Ministry
of Health, Labor and Welfare, as well as the ethical
principles established for research on human beings
as stipulated in the Declaration of Helsinki and fur-
ther amendments thereto.
The protocol has been approved by the institutional
review boards of Kyoto University Medical School on 12
June 2014 (ID: C842), of Nagoya City University on 11
August 2014 (ID: 45-14-0009) and of Kochi Medical
School on 10 September 2014 (ID: ERB-100826). If im-
portant protocol modifications such as changes to eligi-
bility criteria, outcomes, or analyses are needed, the
investigators will discuss them and report to the review
boards for approval.
Written informed consent will be obtained from all
participants included in this study. Data of each partici-
pant will be handled with sequentially allocated numbers
to maintain participant confidentiality.
Data analysis
Details of the planned analyses for the trial will be given
in the Statistical Analysis Plan, to be drafted by the trial
statistician. The analyses will be conducted according to
the plan.
Primary analyses
The primary outcome will be analyzed using a mixed
model with repeated measures to examine treatment ef-
fect parameters of all the eligible subjects in the primary
comparison set according the ITT principle. Allocation
group (intervention) and stratification variables used in
randomization will be incorporated into the model. A
regression coefficient (beta), its 95 % CIs, and a 2-side P
value will be calculated. The statistical significance is set
at 0.05 (2-sided). If the changes are not linear, an appro-
priate model will be applied.
Secondary analyses
We will perform secondary analyses to supplement our
primary analysis and to obtain finer understanding of
our clinical questions. The secondary analyses will use
models similar to those of the primary analysis, will
analyze data from both the primary and secondary com-
parison sets as well as from the per protocol set, and will
also examine data for the secondary outcome measures.
These analyses will be conducted for exploratory pur-
poses. We will not use adjustment for multiple tests. We
will report the effect sizes and their 95 % CIs. The
methods for these secondary analyses will be stated in
detail in the Statistical Analysis Plan.
Interim analyses
We will not perform interim analyses.
Sample size
Sample size was based on a power analysis with 0.8
power to detect an effect size of 0.5 between the groups
at P = 0.05 (2-sided). It was calculated that 63 patients
would be required for each of the two arms for the pri-
mary comparison set. Assuming that 30 % of the initial
entries would drop out or otherwise be classified into
the secondary comparison set at week 1, 164 participants
would need to be recruited into the trial.
The effect size of the Kokoro-App was estimated at
0.5 because we anticipated a medium effect size [33]
compared with the wait-list control group. In fact, an ef-
fect size of 0.69 was observed when we conducted a
clinical trial of a 1-to-1 telephone-based CBT program,
which formed the prototype of the Kokoro-App, in com-
parison with a wait-list control [11]. Systematic reviews
of clinical trials on the efficacy of computer or Internet-
based CBT showed 0.49 [8] and 0.78 [7] in the acute-
phase treatment. We therefore calculate that we could
anticipate an effect size of approximately 0.5 for the
Kokoro-App.
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The primary outcome of the present trial is the change
in the PHQ-9 through weeks 0, 1, 5 and 9. Taking account
of the sample size calculation for repeated measures [34],
a sample size per group will not exceed 63 even when we
consider associations of 4 time points. However, this is de-
rived from presumption that the treatment effect is stable
between any two time points. If there is a large difference
between time points, statistical power would decrease. If
this does occur, we will recalculate and examine the
achieved statistical power post hoc.
Funding
This study is funded by the Pragmatic Psychophar-
macotherapy Research Project initiated by the Japan
Foundation for Neuroscience and Mental Health. The
Project has received donations from Asahi Kasei
Pharma Corp., Eli Lilly Japan KK, GlaxoSmithKline
KK, Ltd., Janssen Pharmaceuticals KK, Meiji Seika
Pharma Co., Mitsubishi Tanabe Pharma Corporation,
MSD KK, Mochida Pharmaceutical Co., Ltd., Otsuka
Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co.,
Ltd., Pfizer Japan Inc., Ltd. and Shionogi & Co. The
up-to-date information will be uploaded on the trial
website (http://ebmh.med.kyoto-u.ac.jp/flatt/) and will
be provided in the informed consent document for
the participant.
Publication policy
The results from the study will be submitted to peer-
reviewed journals. The collaborating researchers have
the right to be named as the first author of these papers
in the order of their number of recruitment. TAF will be
the corresponding author for all the papers.
Trial principal physicians, trial participating physicians
and other members of the Steering Committee, if they
do not appear as co-author, will be listed at the end of
the article. Such authors may be counted as co-authors
in some journals but not in others.
Study period
The study period of this trial will be between September
2014 and March 2017, with the participant entry period
between June 2014 and October 2016.
Discussion
To our knowledge, the present study represents the
first trial investigating the efficacy of smartphone-based
CBT in clinical settings, especially for patients still suf-
fering from depression after an adequate trial of anti-
depressant treatment. Considering the high dropout
rate of computer-based CBT [8], smartphone-based CBT
may offer a more accessible option because patients
can access it anywhere and anytime they have a chance
and are willing to do so. Only fewer than 50 % of
patients receiving acute-phase antidepressant treatment
can achieve remission [4], so that easily accessible CBT
may offer some additional benefits in the treatment of
depression. The present study focuses on patients with
antidepressant-resistant depression, so that targeted
population may be those in most need. If the efficacy of
a smartphone-based CBT program in this population is
confirmed, applicability of the program in real clinical
settings is quite promising.
The present study is, however, not without some meth-
odological limitations. First of all, not all patients who are
interested in and willing to do the Kokoro-App have a
smartphone. This may undermine the applicability of the
results from this trial to all patients with antidepressant-
resistant depression. Especially, the results might not be
applicable to patients in developing countries and to pa-
tients with poor ICT literacy.
Second, we selected a wait-list control as the compara-
tor due to the feasibility and ethical considerations, but
the nocebo effects of the latter condition can play an
important role in the estimation of the efficacy of the
smartphone-based CBT. In a network meta-analysis of
CBTs, waiting-list controls and no treatment controls, the
odds ratio of response for no treatment over waiting-list
was statistically significant at 2.9 (95 % CI: 1.3 to 5.7) [35].
However, in the present trial we planned to switch a previ-
ous antidepressant treatment to a newer drug for each pa-
tient (e.g., sertraline or escitalopram) for all participants at
entry to the study, thus raising expectation across the
intervention and control arms. This might lead to decreas-
ing nocebo effects of the waiting-list control.
Third, one may consider that results from the primary
comparison set are those of an efficacy trial not of an ef-
fectiveness trial, because we would only include patients
who are able to tolerate the trial antidepressant for
1 week and are accustomed to using a smartphone. This
decision was made a priori because the trial is the first
one of this kind. However, we will include patients who
had failed to meet these conditions in our secondary
comparison set, and results from these analyses can be
utilized in future effectiveness trials.
Fourth, although the effect size of 0.5 used for calcula-
tion of sample sizes was estimated from results of the
previous studies on the efficacy of computer or Internet-
based CBT [7, 8], one may think that the effect size is
too optimistic because the present study focuses on pa-
tients with treatment-refractory depression. In addition,
a majority of the control conditions used in trials in-
cluded in previous systematic reviews [7, 8] were
waiting-list, which might have led to plausibly large ef-
fect sizes. However, our previous clinical trial compar-
ing the efficacy of a telephone-based CBT program
added to the employee assistance program with that of
the latter alone showed an effect size of 0.69 [11]. The
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smartphone-based CBT program in the present study
was based on this telephone-based program, and we
considered that the estimated effect size of 0.5 in the
present study was reasonable.
Trial status
The randomized trial, which commenced in September
2014, is currently in the phase of participant enrollment
and follow up.
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